| Literature DB >> 33531830 |
Chiara Angeletti1, Paolo Matteo Angeletti2, Martina Paesani1, Cristiana Guetti3, Aglaia Gyra2, Gianluca Perseo1, Alessandra Ciccozzi2, Franco Marinangeli2, Emma Altobelli4.
Abstract
PURPOSE: Pain is a symptom that should be evaluated along with its comorbidities in order to plan an effective holistic treatment strategy involving specific pharmacological interventions, side effect management, psychological support, control of therapeutic effects over time, and dialogue with the patient and their relatives. In this holistic process of caring for patients with pain, nurses play a central role as they deal with suffering patients directly and continuously. The purpose of this study was to evaluate the types of pain identified by nurses in their daily clinical practice and the associated comorbidities (anamnestic history taking) by geographical region and to evaluate the pharmacological strategies used.Entities:
Keywords: nurse education; pain management; psychological comorbidities
Year: 2021 PMID: 33531830 PMCID: PMC7846823 DOI: 10.2147/JPR.S245792
Source DB: PubMed Journal: J Pain Res ISSN: 1178-7090 Impact factor: 3.133
Geographical distribution of type, frequency, site of pain comorbidity pathologies associated with non-oncological pain
| Variable | Total Responders No. (%) | North-West No. (%) | North-East No. (%) | Centre No. (%) | South No. (%) | p |
|---|---|---|---|---|---|---|
| Type of pain in routine clinical practice | ||||||
| Acute pain | 665 (95.5) | 83 (49.1) | 94 (44.1) | 47 (37.9) | 101 (63.5) | |
| Chronic pain | 40 (23.7) | 59 (27.79 | 40 (32.3) | 24 (15.1) | 0.0008 | |
| Both | 46 (27.2) | 60 (28.1) | 37 (29.8) | 34 (21.3) | ||
| Which is the most frequent type of pain in your routine clinical practice? | ||||||
| Chronic non-oncological | 665 (95.5) | 40 (23.7) | 60 (28.1) | 42 (33.9) | 25 (15.7) | |
| pain | 37 (21.9) | 63 (29.6) | 32 (25.8) | 31 (19.5) | 0.0001 | |
| Chronic oncological pain | 92 (54.4) | 90 (42.2) | 50 (40.3) | 103 (64.8) | ||
| Pathologies associated with non-oncological pain | ||||||
| Rheumatic diseases | 664 (95.4) | 19 (11.3) | 34 (16) | 27 (21.8) | 33 (20.8) | |
| Musculoskeletal system | 57 (33.9) | 72 (33.8) | 40 (32.2) | 69 (43.4) | 0.004 | |
| Cardiovascular system | 16 (9.5) | 19 (8.9) | 6 (4.8) | 3 (1.9) | ||
| Gastrointestinal system | 20 (11.9) | 22 (10.3) | 10 (8.1) | 17 (10.7) | ||
| Dysmetabolic | 5 (3) | 3 (1.4) | 1 (0.8) | 2 (1.3) | ||
| Neurologic | 14 (8.3) | 17 (8) | 23 (18.6) | 10 (6.2) | ||
| Infectious | 3 (1.8) | 3 (1.4) | 3 (2.4) | 3 (1.9) | ||
| Others | 34 (20.3) | 43 (20.2) | 14 (11.3) | 22 (13.8) | ||
| Most frequent sites of pain | ||||||
| Head/neck | 663 (95.3) | 9 (5.3) | 16 (7.5) | 14 (11.3 | 19 (12.1) | |
| Posterior Chest | 25 (14.8) | 27 (12.7) | 24 (19.3) | 37 (23.6) | 0.08 | |
| Anterior Chest | 17 (10.1) | 19 (8.9) | 11 (9.9) | 9 (5.7) | ||
| Abdominal | 44 (26) | 48 (22.5) | 22 (17.7) | 37 (23.6) | ||
| Muscles | 34 (20.1) | 45 (21.1) | 30 (24.1) | 18 (11.5) | ||
| Joints | 38 (22.5) | 54 (25.3) | 21 (16.9) | 34 (21.7) | ||
| Pelvis | 2 (1.2) | 4 (1.9) | 2 (1.6) | 3 (1.9) | ||
| Psychiatric disorders associated | ||||||
| Anxiety | 665 (95.5) | 84 (49.7) | 94 (44.1) | 49 (39.5) | 104 (65.4) | 0.002 |
| Sleeplessness | 26 (15.4) | 27 (12.7) | 27 (21.8) | 16 (10.1) | ||
| Somatization | 13 (7.7) | 20 (9.4) | 18 (14.5) | 10 (6.3) | ||
| Personality disorders | 7 (4.1) | 10 (4.7) | 5 (4) | 4 (2.5) | ||
| Others | 4 (2.4) | 12 (5.6) | 5 (4) | 5 (3.1) | ||
Distribution of drug use in geographic areas considered
| Variable | Total Responders No. (%) | North-West No. (%) | North-East No. (%) | Centre No. (%) | South No. (%) | p |
|---|---|---|---|---|---|---|
| Paracetamol | 665 (95.5) | 125 (74) | 151(70.9) | 82 (66.1) | 109 (68.6) | 0.14 |
| NSAIDs | 31 (18.3) | 42 (19.7) | 32 (25.8) | 26 (16.3) | ||
| Ketorolac | 13 (7.7) | 20 (9.3) | 10 (8.1) | 24 (15.1) | ||
| Codeine+paracetamol | 665 (95.5) | 90 (53.2) | 144 (67.6) | 76 (61.3) | 70 (44) | 0.0005 |
| Tramadol | 39 (23.1) | 36 (16.9) | 23 (18.6) | 43 (27) | ||
| Fentanyl | 27 (16) | 13 (6.1) | 9 (7.2) | 29 (18.2) | ||
| Morphine | 9 (5.3) | 15 (7) | 12 (9.7) | 15 (9.4) | ||
| Otherh | 4 (2.4) | 5 (2.3) | 4 (3.2) | 2 (1.2) | ||
| Combinations | 658 (94.5) | |||||
| Tramadol+paracetamol | 81 (48.2) | 101 (47.6) | 55 (44.39 | 107 (69.5) | 0.001 | |
| Codeine+paracetamol | 78 (46.4) | 103 (48.6) | 59 (47.6) | 41 (26.5) | ||
| Caffeine+paracetamol | 3 (1.8) | 2 (1) | 3 (2.4) | 0 (0) | ||
| Otheri | 6 (3.6) | 6 (2.8) | 7 (5.7) | 6 (3) | ||
| Adjuvants | 637 (91.59) | |||||
| Amitriptyline | 44 (26.3) | 65 (31.2) | 41 (33.1) | 44 (31.9) | 0.09 | |
| Duloxetine | 6 (3.6) | 8 (3.9) | 5 (4) | 4 (2.9) | ||
| Gabapentin | 67 (40.1) | 103 (49.5) | 49 (39.5) | 56 (40.6) | ||
| Pregabalin | 40 (24) | 19 (9.1) | 22 (17.7) | 22 (15.9) | ||
| Bisphosphonates | 10 (6) | 13 (6.2) | 7 (5.7) | 12 (8.7) |
Notes: (h) Oxycodone or buprenorphine or methadone; (i) Oxycodone + paracetamol or oxycodone + naloxone.
Pain modality and comorbidities
| Variable | Total No. (%) | Chronic/Non-Oncological Pain No. (%) | Cancer No. (%) | Acute No. (%) | p |
|---|---|---|---|---|---|
| Psychiatric disorders | |||||
| Anxiety | 690 (100) | 55 (31.8) | 79 (47.6) | 208 (59.2) | <0.0001 |
| Depression | 50 (28.9) | 41 (24.7) | 41 (11.68) | ||
| Sleeplessness | 31 (17.9) | 26 (15.6) | 44 (12.5) | ||
| Somatization | 18 (10.4) | 12 (7.2) | 34 (9.7) | ||
| Mood disorders | 14 (8.9) | 2 (1.2) | 9 (2.5) | ||
| Others | 5 (2.8) | 6 (3.6) | 15 (4.3) | ||
| Pathologies associated | |||||
| Rheumatic | 689 | 37 (21.5) | 39 (23.5 | 45 (12.8) | |
| Musculoskeletal system | (99.8) | 62 (36.1) | 61 (36.7 | 121 (34.5) | 0.0001 |
| Cardiovascular system | 9 (5.2) | 9 (5.4 | 29 (8.3) | ||
| Gastrointestinal system | 9 (5.2) | 23 (13.8 | 38 (10.8) | ||
| Dysmetabolic | 10 (5.8) | 0 (0) | 1 (0.3) | ||
| Neurologic | 26 (15.1) | 22 (13.2) | 18 (5.1) | ||
| Infectious | 3 (1.7) | 3 (1.8) | 7 (2.0) | ||
| Others | 16 (9.3) | 9 (5.4) | 92 (26.2) | ||